Jubilant Biosys Ltd. and Endo Pharmaceuticals have achieved a late-stage discovery milestone in their joint oncology program. This marks the third milestone in the two-year-old, multi-target partnership, and enables the collaboration to rapidly pursue a development candidate. As a part of the partnership, Jubilant delivers preclinical development candidates and has an option to participate in clinical development. Endo owns the development and commercial rights to the successful outcomes. Jubilant derives research funding, development milestones and sales royalties on successful commercialization.

Sri Mosur, Jubilant's chief executive officer and president, Global Drug Discovery & Development, said, "We are pleased that we continue to enhance the portfolio outcomes for Endo Pharmaceuticals. It is an important achievement in our collaboration and demonstrates our scientist's commitment to oncology research to deliver differentiated therapies to cancer patients worldwide. It will be our continued endeavor to support the collaboration in accelerating the development phase towards successful commercialization"

Sandeep Gupta, Endo's senior vice president, Discovery and Early Development, added, "We are pleased with the technical capabilities and productivity of the Jubilant team. They have done an outstanding job of designing novel molecules and to demonstrate preclinical proof of concept ahead of schedule. We look forward to nominating a development candidate in the near future."